NCT02992977View on ClinicalTrials.gov

Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Advanced Cancer
Interventions
BIOLOGICAL

AutoSynVax™ vaccine

AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant

Trial Locations (2)

33136

School of Medicine at the University of Miami, Miami

43210

The Ohio State University Comprehensive Cancer Center, Columbus

Sponsors

Lead Sponsor

Agenus Inc.
All Listed Sponsors
lead

Agenus Inc.

INDUSTRY

NCT02992977 - Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer | Biotech Hunter | Biotech Hunter